Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in
interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is
a medication that comes from the bacteria Clostridium botulinum. It works by blocking the
release of the neurotransmitter acetylcholine(a chemical messenger that carries signals
between nerve cells and other cells in the body). Blocking that neurotransmitter results in
decreased muscle activity.
Phase:
Phase 4
Details
Lead Sponsor:
Robert J. Evans, M.D. Wake Forest University Health Sciences
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA